Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to pharmaceutical pricing and biosimilars.
H.R.5376 - Inflation Reduction Act of 2022.
Issues related to the Prescription Drug User Fee Act (PDUFA).
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs.
H.R.5376 - Inflation Reduction Act of 2022.
Issues relating to tax and trade. Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to pharmaceutical pricing and biosimilars.
H.R.5376 - Inflation Reduction Act of 2022.
International IP issues.
Duration: September 1, 2012
to
December 31, 2022
General Issues: Health Issues , Medicare/Medicaid , Taxation/Internal Revenue Code , Trade (Domestic & Foreign) , Medical/Disease Research/Clinical Labs , Foreign Relations
Spending: about $2,080,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2012: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Alex DelPizzo LD/LA,Rep.Ferguson;Transp&InfrastructureCmte
Legislative Director/Legislative Asst, Rep. Ferguson; Staff Asst, House Transportation and Infrastructure Committee
Andrew Rosenberg Leg Asst, Kennedy; Leg Aide, Senate HELP Comm
Jessie Brairton SrLA/LA:CongL.Smith;LC,Asst:SenAgingComm
Senior Legislative Asst/Legislative Asst, Rep. Lamar Smith; LC/Asst, Senate Special Aging Committee
W. Christopher Lamond Aide, Senate Govt Affairs Comm; LA, Sen. Thompson
Gary Palmquist LegDir-Dennis Cardoza,Bob Clement,Ken Bentsen
Legislative Director: Rep. Dennis Cardoza, Rep. Bob Clement, Rep. Ken Bentsen
Charles Thomas Senior Legislative Asst, Legislative Asst, Legislative Aide, Staff Asst; Rep. Robert Pittenger
Beau Schuyler Legislative Director: Rep. Tanner; Legislative Director: Rep. McIntyre
Richard White n/a
Shea McCarthy n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2022
Thorn Run Partners terminated an engagement in which they represented Novartis Corporation on Jan. 18, 2023.
Original Filing: 301430341.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to pharmaceutical pricing and biosimilars.
H.R.5376 - Inflation Reduction Act of 2022.
Issues related to the Prescription Drug User Fee Act (PDUFA).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs.
H.R.5376 - Inflation Reduction Act of 2022.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to tax and trade. Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to pharmaceutical pricing and biosimilars.
H.R.5376 - Inflation Reduction Act of 2022.
International IP issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2022
In Q3, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on Oct. 20, 2022.
Original Filing: 301420145.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to pharmaceutical pricing and biosimilars.
H.R.5376 - Inflation Reduction Act of 2022.
Issues related to the Prescription Drug User Fee Act (PDUFA).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs.
H.R.5376 - Inflation Reduction Act of 2022.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to tax and trade. Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to pharmaceutical pricing and biosimilars.
H.R.5376 - Inflation Reduction Act of 2022.
International IP issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2022
In Q2, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on July 20, 2022.
Original Filing: 301390794.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to pharmaceutical pricing and biosimilars.
Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Issues related to the Prescription Drug User Fee Act (PDUFA).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs.
Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to tax and trade. Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to pharmaceutical pricing and biosimilars.
Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
International IP issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2022
In Q1, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on April 20, 2022.
Original Filing: 301371809.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to pharmaceutical pricing and biosimilars.
Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs.
Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues relating to tax and trade. Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to pharmaceutical pricing and biosimilars.
Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2021
In Q4, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on Jan. 19, 2022.
Original Filing: 301328075.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to pharmaceutical pricing and biosimilars.
Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs.
Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on Oct. 20, 2021.
Original Filing: 301314018.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to pharmaceutical pricing and biosimilars.
Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs.
Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on July 20, 2021.
Original Filing: 301288190.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to pharmaceutical pricing and biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on April 20, 2021.
Original Filing: 301261442.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to pharmaceutical pricing and biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on Jan. 20, 2021.
Original Filing: 301240497.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to pharmaceutical pricing and biosimilars.
H.R. 133, Consolidating Appropriations Act, 2021.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs.
H.R. 133, Consolidating Appropriations Act, 2021.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on Oct. 20, 2020.
Original Filing: 301219885.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to pharmaceutical pricing and biosimilars.
The Cares Act (P.L. 116-136).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs.
The Cares Act (P.L. 116-136).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on July 20, 2020.
Original Filing: 301195959.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to pharmaceutical pricing and biosimilars.
H.R. 19, Lower Costs, More Cures Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs.
H.R. 19, Lower Costs, More Cures Act of 2019.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on April 20, 2020.
Original Filing: 301174843.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to pharmaceutical pricing and biosimilars.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.
H.R. 19, Lower Costs, More Cures Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.
H.R. 19, Lower Costs, More Cures Act of 2019.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on Jan. 21, 2020.
Original Filing: 301128382.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to pharmaceutical pricing and biosimilars.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.
H.R. 19, Lower Costs, More Cures Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.
H.R. 19, Lower Costs, More Cures Act of 2019.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
Thorn Run Partners amended a lobbying report for representation of Novartis Corporation in Q32019 on Oct. 30, 2019.
Original Filing: 301080413.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to pharmaceutical pricing and biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on Oct. 15, 2019.
Original Filing: 301066147.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on July 18, 2019.
Original Filing: 301048461.xml
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare and Medicaid reimbursement of biosimilars and drugs.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on April 17, 2019.
Original Filing: 301027754.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Neonatal drug issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to the Part D coverage gap and the Medicare reimbursement of biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the Orphan Drug Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2018
In Q4, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on Jan. 18, 2019.
Original Filing: 301010342.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Neonatal drug issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to the Part D coverage gap and the Medicare reimbursement of biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the Orphan Drug Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2018
Thorn Run Partners amended a lobbying report for representation of Novartis Corporation in Q32018 on Jan. 18, 2019.
Original Filing: 301010383.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Neonatal drug issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to the Part D coverage gap and the Medicare reimbursement of biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the Orphan Drug Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2018
In Q3, Thorn Run Partners lobbied for Novartis Corporation , earning $60,000. The report was filed on Oct. 19, 2018.
Original Filing: 300990560.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Neonatal drug issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to the Part D coverage gap and the Medicare reimbursement of biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the Orphan Drug Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2018
In Q2, Thorn Run Partners lobbied for Novartis Corporation , earning $60,000. The report was filed on July 18, 2018.
Original Filing: 300968906.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Neonatal drug issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to the Part D coverage gap and the Medicare reimbursement of biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the Orphan Drug Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Legislation related to CFIUS and FARA including issues related to critical technologies and export controls;
S.2098/H.R.4311, Foreign Investment Risk Review Modernization Act of 2017;
S.2482, Foreign Agents Registration Amendments Act of 2018.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Thorn Run Partners lobbied for Novartis Corporation , earning $60,000. The report was filed on April 19, 2018.
Original Filing: 300951834.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Neonatal drug issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Issues related to the Part D coverage gap and the Medicare reimbursement of biosimilars; H.R.1892, Bipartisan Budget Act of 2018 (P.L.115-123); H.R.1625, Consolidated Appropriations Act, 2018 (P.L.115-141).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the Orphan Drug Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Legislation related to CFIUS and FARA including issues related to critical technologies and export controls; S.2098/H.R.4311, Foreign Investment Risk Review Modernization Act of 2017; S.2482, Foreign Agents Registration Amendments Act of 2018.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Thorn Run Partners lobbied for Novartis Corporation , earning $60,000. The report was filed on Jan. 20, 2018.
Original Filing: 300931433.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148). Neonatal drug issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the Orphan Drug Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2017
In Q3, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on Oct. 19, 2017.
Original Filing: 300908730.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148). Neonatal drug issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the Orphan Drug Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2017
In Q2, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on July 17, 2017.
Original Filing: 300886481.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148). Neonatal drug issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the Orphan Drug Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2017
In Q1, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on April 17, 2017.
Original Filing: 300866834.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148). Neonatal drug issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the Orphan Drug Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2016
In Q4, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on Jan. 16, 2017.
Original Filing: 300846592.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148). S.2041, Promoting Life-Saving New Therapies for Neonates Act of 2015/H.R.5182, Promoting Life-Saving New Therapies for Neonates Act of 2016; neonatal drug issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3618, Orphan Drug Fairness Act; P.L.114-113, Protecting Americans from Tax Hikes Act of 2015 and Consolidated Appropriations Act, 2016; issues related to the Orphan Drug Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2016
In Q3, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on Oct. 18, 2016.
Original Filing: 300829660.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148). S.2041, Promoting Life-Saving New Therapies for Neonates Act of 2015/H.R.5182, Promoting Life-Saving New Therapies for Neonates Act of 2016; neonatal drug issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3618, Orphan Drug Fairness Act; P.L.114-113, Protecting Americans from Tax Hikes Act of 2015 and Consolidated Appropriations Act, 2016; issues related to the Orphan Drug Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2016
In Q2, Thorn Run Partners lobbied for Novartis Corporation , earning $90,000. The report was filed on July 18, 2016.
Original Filing: 300812179.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148). S.2041, Promoting Life-Saving New Therapies for Neonates Act of 2015/H.R.5182, Promoting Life-Saving New Therapies for Neonates Act of 2016; neonatal drug issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L.111-148).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3618, Orphan Drug Fairness Act; P.L.114-113, Protecting Americans from Tax Hikes Act of 2015 and Consolidated Appropriations Act, 2016; issues related to the Orphan Drug Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2016
In Q1, Thorn Run Partners lobbied for Novartis Corporation , earning $90,000. The report was filed on April 19, 2016.
Original Filing: 300797264.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L. 111-148). S.2041, Promoting Life-Saving New Therapies for Neonates Act of 2015; neonatal drug issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L. 111-148).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3618, Orphan Drug Fairness Act; P.L.114-113, Protecting Americans from Tax Hikes Act of 2015 and Consolidated Appropriations Act, 2016; issues related to the Orphan Drug Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2015
Thorn Run Partners amended a lobbying report for representation of Novartis Corporation in Q42015 on April 19, 2016.
Original Filing: 300797272.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L. 111-148). S.2041, Promoting Life-Saving New Therapies for Neonates Act of 2015; neonatal drug issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L. 111-148).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3618, Orphan Drug Fairness Act; P.L.114-113, Protecting Americans from Tax Hikes Act of 2015 and Consolidated Appropriations Act, 2016; issues related to the Orphan Drug Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2015
In Q4, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on Jan. 17, 2016.
Original Filing: 300773700.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L. 111-148). S.2041, Promoting Life-Saving New Therapies for Neonates Act of 2015; neonatal drug issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L. 111-148).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3618, Orphan Drug Fairness Act; P.L.114-113, Protecting Americans from Tax Hikes Act of 2015 and Consolidated Appropriations Act, 2016; issues related to the Orphan Drug Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2015
In Q3, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on Oct. 16, 2015.
Original Filing: 300754750.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L. 111-148). S.2041, Promoting Life-Saving New Therapies for Neonates Act of 2015; neonatal drug issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L. 111-148).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.3618, Orphan Drug Fairness Act; issues related to the Orphan Drug Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2015
In Q2, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on July 16, 2015.
Original Filing: 300736657.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L. 111-148).
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
Lobbying Issues
Issues related to the Orphan Drug Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2015
In Q1, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on April 16, 2015.
Original Filing: 300716771.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L. 111-148).
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
Lobbying Issues
Issues related to the Orphan Drug Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2014
In Q4, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on Jan. 16, 2015.
Original Filing: 300698522.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L. 111-148).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Medicaid
Lobbying Issues
Issues related to the Orphan Drug Tax and Tax Extenders; S.2260, EXPIRE Act of 2014; H.R.5771, Tax Increase Prevention Act of 2014.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2014
In Q3, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on Oct. 16, 2014.
Original Filing: 300677904.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L. 111-148).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Medicaid
Lobbying Issues
Issues related to the Orphan Drug Tax and Tax Extenders; S.2260, EXPIRE Act of 2014.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2014
In Q2, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on July 17, 2014.
Original Filing: 300659469.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L. 111-148).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Medicaid
Lobbying Issues
Issues related to the Orphan Drug Tax and Tax Extenders; S.2260, EXPIRE Act of 2014.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2014
In Q1, Thorn Run Partners lobbied for Novartis Corporation , earning $50,000. The report was filed on April 17, 2014.
Original Filing: 300639443.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Implementation issues related to the Patient Protection and Affordable Care Act (P.L. 111-148).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Medicaid
Lobbying Issues
Issues related to the Orphan Drug Tax and Tax Extenders.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2013
In Q4, Thorn Run Partners lobbied for Novartis Corporation , earning $30,000. The report was filed on Jan. 16, 2014.
Original Filing: 300617229.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to Patient Protection and Affordable Care Act (PPACA) implementation.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Health Issues/Medicaid
3rd Quarter, 2013
In Q3, Thorn Run Partners lobbied for Novartis Corporation , earning $30,000. The report was filed on Oct. 17, 2013.
Original Filing: 300596590.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to healthcare.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, Thorn Run Partners lobbied for Novartis Corporation , earning $30,000. The report was filed on July 18, 2013.
Original Filing: 300575726.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to healthcare.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, Thorn Run Partners lobbied for Novartis Corporation , earning $30,000. The report was filed on April 17, 2013.
Original Filing: 300552547.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to healthcare.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, Thorn Run Partners lobbied for Novartis Corporation , earning $30,000. The report was filed on Jan. 19, 2013.
Original Filing: 300535887.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to healthcare.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, Thorn Run Partners lobbied for Novartis Corporation , earning $10,000. The report was filed on Oct. 17, 2012.
Original Filing: 300509930.xml
Lobbying Issues
Issues related to biologics.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Issues related to healthcare.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
Thorn Run Partners filed a lobbying registration on Sept. 25, 2012 to represent Novartis Corporation, effective Sept. 1, 2012.
Original Filing: 300503264.xml
Issue(s) they said they’d lobby about: Issues related to biologics, healthcare and Medicare. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...